NK1 (substance P) receptor antagonists - Why are they not analgesic in humans?

Trends in Pharmacological Sciences

Volumn 21, Issue 7, 2000, Pages 244-246

  Hill, Ray ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; SUBSTANCE P; SUBSTANCE P ANTAGONIST;

ANALGESIA; HUMAN; KNOCKOUT MOUSE; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; SPINAL CORD DORSAL HORN; TRIGEMINUS NEURALGIA; ANIMAL; DRUG ANTAGONISM; DRUG SCREENING; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW;

ANALGESIA; ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; MICE, KNOCKOUT; PAIN; RECEPTORS, NEUROKININ-1; SPECIES SPECIFICITY; SUBSTANCE P;

EID: 0034214841     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01502-9     Document Type: Note

References (18)

1. th World Congress on Pain. 2000;313-324 IASP Press.
2. 1) antagonists. Trends Pharmacol. Sci. 20:1999;485-490.
3. Von Euler U.S. The history of substance P. Bousfield D. Neurotransmitters in Action. 1985;143-150 Elsevier Biomedical Press.
4. Salt T.E., Hill R.G. Neurotransmitter candidates of somatosensory primary afferent fibres. Neuroscience. 10:1983;1083-1103.
5. Strittmatter M.et al. Cerebrospinal fluid neuropeptides and monoaminergic transmitters in patients with trigeminal neuralgia. Headache. 37:1997;211-217.
6. Averill S.et al. Immunocytochemical localization of trkA receptors in chemically identified subgroups of adult rat sensory neurons. Eur. J. Neurosci. 7:1995;1484-1494.
7. Levine J.D.et al. Peptides and the primary afferent nociceptor. J. Neurosci. 13:1993;2273-2286.
8. Woolf C.J., Mannion R.J. Neuropathic pain. aetiology, symptoms, mechanisms and management Lancet. 353:1999;1959-1964.
9. Mantyh P.W.et al. Inhibition of hyperalgesia by ablation of lamina-I spinal neurons expressing the substance P receptor. Science. 278:1997;275-279.
10. Ma Q.-P., Hill R.G. Neurokinin antagonists as potential agents for use in pain management. Curr. Opin. Invest. Drugs. 1:1999;65-71.
11. Rupniak N.M.J., Hill R.G. Neurokinin antagonists. Sawynok J., Cowan A. Novel Aspects of Pain Management: Opioids and Beyond. 1999;135-155 Wiley-Liss.
12. 1 antagonists. Curr. Opin. Invest. Drugs. 1:1999;82-85.
13. Chan C.C.et al. Rofecoxib [Vioxx, MK-0966, 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]. a potent andorally active cyclo-oxygenase2 inhibitor. Pharmacological and biochemical profiles J. Pharmacol. Exp. Ther. 290:1999;551-560.
14. Baulmann J.et al. Tachykinin receptor inhibition and c-fos expression in the rat brain following formalin induced pain. Neuroscience. 95:2000;813-820.
15. Headley P.M., Livingston A. Pain and stress in animals. problems of assessment and treatment Front. Pain. 1:1989;1-4.
16. Bodkin J.A.et al. Buprenorphine treatment of refractory depression. J. Clin. Psychopharmacol. 15:1995;49-57.
17. Loeser J.D., Melzack R. Pain. an overview Lancet. 353:1999;1607-1609.
18. Langley G.et al. Volunteer studies replacing animal experiments in brain research. Alternatives to Laboratory Animals. 28:2000;315-331.